Axsome Therapeutics, Inc.
NASDAQ:AXSMBiotechnology
+$0.25 today
- Market cap
- $7.05B
- Beta
- 0.60
- P/E (TTM)
- -68.6
- EPS (TTM)
- -$3.68
Volume 0.74M
Average 0.72M
AXSM Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Axsome Therapeutics, Inc.NASDAQ: AXSM
Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026
Depreciation & amortization growth accelerates
Q2 FY2026 depreciation & amortization of $2.89M rose 28.5% year over year, ahead of the +16.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 22.0% from the prior quarter. Over 3 fiscal years it compounded at +27.2% a year.
Context
- Depreciation & amortization amounted to 1.4% of revenue in FY2025, down 0.6 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +28.5% holds above the trailing-twelve-month pace of +16.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 9.06M USD
- Year-over-year change
- +13.9%
- 4-year CAGR
- +230.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.06M | +13.9% |
| FY2024 | 2024-12-31 | 7.96M | +16.4% |
| FY2023 | 2023-12-31 | 6.83M | +55.2% |
| FY2022 | 2022-12-31 | 4.4M | +5692.1% |
| FY2021 | 2021-12-31 | 76K | — |
Depreciation & Amortization vs competitors
How AXSM compares with its peers on the latest reported figures
- AXSM's LTM Jun 2026 depreciation & amortization of $9.94M is the 5th largest of the 11 companies compared; the peer median is $1.66M.
- Its year-over-year change of +16.8% is the 4th highest of 10, against a peer median of +4.8%.
- Depreciation & amortization amounts to 1.3% of revenue for AXSM, versus a peer median of 12.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $718.57M | +4.8% | +3.4% | 15.2% | |
| LTM Jun 2026 | $101.71M | +26.1% | +2.3% | 12.2% | |
| LTM Sep 2026 | $83.6M | +181.5% | +24.5% | 2.3% | |
| LTM Jun 2026 | $13.14M | +17.5% | +12.6% | 364.7% | |
| LTM Jun 2026 | $9.94M | +16.8% | +27.2% | 1.3% | |
| LTM Sep 2026 | $2.32M | -9.6% | +21.9% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1M | +7.4% | +296.1% | 5.0% |
| LTM Sep 2026 | $133K | -16.4% | -30.6% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $59K | -90.6% | -29.5% | — |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $0 | -100.0% | — | — |
| LTM Dec 2025 | $0 | — | — | — | |
| Peer median (excluding AXSM) | $1.66M | +4.8% | +8.0% | 12.2% | |
Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (130.4M) | (187.13M) | (239.24M) | (287.22M) | (183.17M) |
| Depreciation & Amortization | 76K | 4.4M | 6.83M | 7.96M | 9.06M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 20.8M | 37.73M | 62.62M | 85.22M | 93.75M |
| Change in Working Capital | 324K | 23.67M | (28.39M) | 33.9M | (22.52M) |
| Accounts Receivables | 0 | (37.7M) | (57.12M) | (47.18M) | (82.46M) |
| Inventory | (6K) | (5.28M) | (8.16M) | (2.44M) | (15.67M) |
| Accounts Payables | (355K) | 25.46M | 2.07M | 31.32M | (6.46M) |
| Other Working Capital | 685K | 41.19M | 34.81M | 52.2M | 82.07M |
| Other Non-Cash Items | 974K | 4.83M | 53.1M | 31.73M | 9.48M |
| Operating Cash Flow | (108.23M) | (116.51M) | (145.08M) | (128.41M) | (93.41M) |
| Capital Expenditures | (308K) | (702K) | (582K) | (270K) | (480K) |
| Acquisitions (Net) | 0 | (53M) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (308K) | (53.7M) | (582K) | (270K) | (480K) |
| Debt Repayment | 0 | 45M | 85M | (990K) | (7.75M) |
| Common Stock Issued | 7.44M | 243.76M | 258.75M | 40.78M | 126.27M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.69M | (4.18M) | (12.74M) | 18.05M | (17.05M) |
| Financing Cash Flow | 11.13M | 284.58M | 331.01M | 57.84M | 101.47M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (97.4M) | 114.37M | 185.35M | (70.84M) | 7.58M |
| Free Cash Flow | (108.53M) | (117.21M) | (145.66M) | (128.68M) | (93.89M) |
Axsome Therapeutics, Inc.
NASDAQ:AXSM
Intrinsic Alpha fair value
Locked
Current Price
$134.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.